Targeted therapy in older adults with Alzheimer disease: a review

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

One of the most pressing issues today is the somatic and mental health of older adults due to increasing life expectancy and expanding diagnostic capabilities for various diseases.

Alzheimer disease has a significant impact on the quality of life of patients and their families and results in substantial economic and social consequences for society. Patients with Alzheimer disease require continuous care and support, which demands considerable resources from health care and social service systems. Moreover, Alzheimer disease leads to reduced work productivity and increased health care expenditures.

This review analyzes foreign and Russian articles published in the past 5 years in Scopus, PubMed Central, the Cochrane Library, and BMJ Case Reports regarding targeted therapy for Alzheimer disease, one of the most common neurodegenerative disorders that reduce quality of life. This review considers the main principles of targeted therapy used in older adults with Alzheimer disease are considered, along with its advantages, limitations, and future perspectives for this therapeutic approach.

Full Text

Restricted Access

About the authors

Polina A. Bulina

North-Western State Medical University named after I.I. Mechnikov

Author for correspondence.
Email: pollybulina@mail.ru
ORCID iD: 0009-0002-2633-7501
SPIN-code: 8752-4164
Russian Federation, 41 Kirochnaya st, Saint Petersburg, 191015

Polina A. Popova

North-Western State Medical University named after I.I. Mechnikov

Email: apolinaria_2002@mail.ru
ORCID iD: 0009-0003-1947-1443
Russian Federation, Saint Petersburg

Lyubov S. Dyatchina

North-Western State Medical University named after I.I. Mechnikov

Email: lyubov.dyatchina@mail.ru
ORCID iD: 0009-0000-7558-4555
Russian Federation, Saint Petersburg

Maria M. Goliatina

Saint-Petersburg State Pediatric Medical University

Email: padalekimary@mail.ru
ORCID iD: 0009-0000-3798-3600
Russian Federation, Saint Petersburg

Anastasia P. Zaitseva

Saint-Petersburg State Pediatric Medical University

Email: super.z-nastia@ya.ru
ORCID iD: 0009-0001-0131-025X
Russian Federation, Saint Petersburg

Anastasiia A. Abramenko

Academician I.P. Pavlov First St. Petersburg State Medical University

Email: nabramenko32@gmail.com
ORCID iD: 0009-0005-8777-1055
Russian Federation, Saint Petersburg

Kirill P. Raevskii

Lomonosov Moscow State University

Email: raevskiikp@my.msu.ru
ORCID iD: 0000-0002-9939-3443
SPIN-code: 9133-3802
Russian Federation, Moscow

References

  1. Tkacheva ON, Frolova EV, Yakhno NN, editors. Geriatrics. Moscow: GEOTAR-Media; 2019. (In Russ.)
  2. Alzheimer’s Disease International. Long S, editor. World Alzheimer Report 2023: Reducing dementia risk: never too early, never too late. Available at: https://www.alzint.org/u/World-Alzheimer-Report-2023.pdf
  3. Melnikov AM, Popugailo MV. Analysis of the pharmaceutical market of drugs for the treatment of Alzheimer's disease. Sovremennye problemy zdravoohranenija i medicinskoj statistiki. 2022;(5):94–106. doi: 10.24412/2312-2935-2022-5-94-106 EDN: WNEJBY
  4. Nasaeva ED, Khasanova EM, Gankovskaya LV. Immunopathogenesis and target therapy of Alzheimer’s disease. Immunologiya. 2023;44(2):231–242. doi: 10.33029/0206-4952-2023-44-2-231-242 EDN: RNKUGO
  5. Volobuyev A, Romanchuk P, Romanchuk N, et al. Polymorphism of the apoe gene: prevalence of phenotypes in the population and an association with the development of Alzheimer's disease. Vrach. 2023;34(6):73–75. doi: 10.29296/25877305 EDN: SJQFDG
  6. Litvinenko IV, Emelin AYu, Lobzin VYu, et al. The amyloid hypothesis of alzheimer's disease: past and present, hopes and disappointments. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(3):4–10. doi: 10.14412/2074-2711-2019-3-4-10 EDN: WGKGKA
  7. Nikolaeva NS, Yandulova EY, Aleksandrova YR, et al. The role of a pathological interaction between β-amyloid and mitochondria in the occurrence and development of Alzheimer's disease. Acta Naturae. 2022;14(3):19–34. doi: 10.32607/actanaturae.11723 EDN: MMRSJD
  8. Abdullayeva N, Aliyeva G. The relationship of tau-protein with the pathology of Alzheimer’S disease. Norwegian Journal of Development of the International Science. 2021;63-1:9–12. doi: 10.24412/3453-9875-2021-63-1-9-12 EDN: FIOIBC
  9. Soibnazarov OJe. The role of immunological factors in the pathogenesis of Alzheimer’s disease. Research Focus International Scientific Journal. 2023;2(12):132–139. doi: 10.5281/zenodo.10406458
  10. Mamchur AA, Erema VV, Kashtanova DA, et al. Molecular dynamics simulation of the conformational mobility of the lipid-binding site in the apolipoprotein E isoforms Ε2, Ε3, and Ε4. Vestnik Moskovskogo Universiteta. Seriya 16. Biologiya. 2023;78(2):70–77. doi: 10.55959/MSU0137-0952-16-78-2-3 EDN: HATRJQ
  11. Preobrazhenskaya IS, Snitskaya NS. The development and treatment of Alzheimer’s disease: Some genetic aspects. Neurology, Neuropsychiatry, Psychosomatics. 2014;6(4):51–58. doi: 10.14412/2074-2711-2014-4-51-58
  12. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535–562. doi: 10.1016/j.jalz.2018.02.018
  13. Leuzy A, Mattsson-Carlgren N, Palmqvist S, et al. Blood-based biomarkers for Alzheimer's disease. EMBO Mol Med. 2022;14(1):e14408. doi: 10.15252/emmm.202114408 EDN: TAFZIS
  14. Guzmán-Martínez L, Tapia JP, Farías GA, et al. The Alz-tau biomarker for Alzheimer's Disease: Study in a Caucasian population. J Alzheimers Dis. 2019;67(4):1181–1186. doi: 10.3233/JAD-180637
  15. Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024;20(8):5143–5169. doi: 10.1002/alz.13859 EDN: SAWTAL
  16. Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurol. 2021;20(6):484–496. doi: 10.1016/S1474-4422(21)00066-1 EDN: SIIFOM
  17. Kotsenko YuI, Nesterov VS. Modern methods for early diagnosis of Alzheimer’s disease. Universiti Clinic. 2024;(2):77-82. EDN: EUWPFM
  18. Twarowski B, Herbet M. Inflammatory processes in Alzheimer's Disease — Pathomechanism, diagnosis and treatment: A review. Int J Mol Sci. 2023;24(7):6518. doi: 10.3390/ijms24076518 EDN: YKFCDD
  19. Beata BK, Wojciech J, Johannes K, et al. Alzheimer's disease — biochemical and psychological background for diagnosis and treatment. Int J Mol Sci. 2023;24(2):1059. doi: 10.3390/ijms24021059 EDN: ISLDBJ
  20. Dubois B, von Arnim CAF, Burnie N, et al. Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants. Alzheimers Res Ther. 2023;15(1):175. doi: 10.1186/s13195-023-01314-6 EDN: NVCPMK
  21. Rajput S, Malviya R, Bahadur S, Puri D. Recent updates on the development of therapeutics for the targeted treatment of Alzheimer's disease. Curr Pharm Des. 2023;29(35):2802–2813. doi: 10.2174/0113816128274618231105173031 EDN: DOTZMA
  22. Toader C, Dobrin N, Brehar FM, et al. From recognition to remedy: The significance of biomarkers in neurodegenerative disease pathology. Int J Mol Sci. 2023;24(22):16119. doi: 10.3390/ijms242216119 EDN: ROUTMW
  23. Nicoll JAR, Buckland GR, Harrison CH, et al. Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer's disease. Brain. 2019;142(7):2113–2126. doi: 10.1093/brain/awz142
  24. Monteiro AR, Barbosa DJ, Remião F, Silva R. Alzheimer's disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. Biochem Pharmacol. 2023;211:115522. doi: 10.1016/j.bcp.2023.115522 EDN: UFIHRA
  25. Hassan NA, Alshamari AK, Hassan AA, et al. Advances on therapeutic strategies for Alzheimer's disease: From medicinal plant to nanotechnology. Molecules. 2022;27(15):4839. doi: 10.3390/molecules27154839 EDN: TFSHEH
  26. Ghisays V, Lopera F, Goradia DD, et al. PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease-causing Presenilin-1 E280A mutation carriers. Neuroimage Clin. 2021;31:102749. doi: 10.1016/j.nicl.2021.102749 EDN: SJUNNI
  27. Su IJ, Chang HY, Wang HC, Tsai KJ. A curcumin analog exhibits multiple biologic effects on the pathogenesis of Alzheimer's disease and improves behavior, inflammation, and β-amyloid accumulation in a mouse model. Int J Mol Sci. 2020;21(15):5459. doi: 10.3390/ijms21155459 EDN: DOQTEY
  28. Dolton MJ, Chesterman A, Moein A, et al. Safety, tolerability, and pharmacokinetics of high-volume subcutaneous Crenezumab, with and without recombinant human hyaluronidase in healthy volunteers. Clin Pharmacol Ther. 2021;110(5):1337–1348. doi: 10.1002/cpt.2385 EDN: NQRYLC
  29. Venegas C, Heneka MT. Inflammasome-mediated innate immunity in Alzheimer's disease. FASEB J. 2019;33(12):13075–13084. doi: 10.1096/fj.201900439
  30. Garanina EE, Martynova EV, Ivanov KY, et al. Inflammasomes: role in disease pathogenesis and therapeutic potential. Uchenye zapiski Kazanskogo Universiteta. Seriya Estestvennye nauki. 2020;162(1):80–111. doi: 10.26907/2542-064X.2020.1.80-111 EDN: CFDRQF
  31. Kuwar R, Rolfe A, Di L, et al. A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury. J Neuroinflammation. 2019;16(1):81. doi: 10.1186/s12974-019-1471-y EDN: AJZKNZ
  32. Iwatsubo T. Molecular pathogenesis and disease-modifying therapies of Alzheimer's disease and related disorders. JMA J. 2022;5(3):307–313. doi: 10.31662/jmaj.2022-0079 EDN: QSDZYI
  33. VandeVrede L, Gibbs DM, Koestler M, et al. Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab. Alzheimers Dement (Amst). 2020;12(1):e12101. doi: 10.1002/dad2.12101 EDN: NUJFGM
  34. Vorobev SV, Emelin AYu, Yanishevskij SN. The evolution of ideas about the treatment of Alzheimer’s disease: from the past to the present day. Russian Neurological Journal. 2022;27(1):5–15. doi: 10.30629/2658-7947-2022-27-1-5-15 EDN: FHDDKL
  35. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–446. doi: 10.1016/S0140-6736(20)30367-6 EDN: VAADCC
  36. Cummings J, Zhou Y, Lee G, et al. Alzheimer's disease drug development pipeline: 2024. Alzheimers Dement (N Y). 2024;10(2):e12465. doi: 10.1002/trc2.12465 EDN: SSQWOI
  37. Bittar A, Bhatt N, Kayed R. Advances and considerations in AD tau-targeted immunotherapy. Neurobiol Dis. 2020;134:104707. doi: 10.1016/j.nbd.2019.104707 EDN: WSNFUN
  38. Congdon EE, Ji C, Tetlow AM, et al. Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat Rev Neurol. 2023;19(12):715–736. doi: 10.1038/s41582-023-00883-2 EDN: JVSQMF
  39. Yu TW, Lane HY, Lin CH. Novel therapeutic approaches for Alzheimer's disease: An updated review. Int J Mol Sci. 2021;22(15):8208. doi: 10.3390/ijms22158208 EDN: YWNFDH
  40. Cummings J, Lee G, Zhong K, et al. Alzheimer's disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021;7(1):e12179. doi: 10.1002/trc2.12179 EDN: SEQCOR
  41. Hamano T, Enomoto S, Shirafuji N, et al. Autophagy and tau protein. Int J Mol Sci. 2021;22(14):7475. doi: 10.3390/ijms22147475 EDN: PASCDG

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия  ПИ № ФС 77 - 86296 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80632 от 15.03.2021 г.